← Back to Analyst Consensus 
RNAM Hold
Avidity Biosciences, Inc.
Current Price —
Implied Upside —
Analysts 20
30-Day Momentum
▲ 0 upgrades / ▼ 0 downgrades / 0 reiterations from 0 firms
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Nov 11, 2025 | Chardan Capital | maintain | Neutral → Neutral | $72 | 47% |
| Oct 29, 2025 | TD Cowen | downgrade | Buy → Hold | $74 | 54% |
| Oct 28, 2025 | Chardan Capital | downgrade | Buy → Neutral | $72 | 47% |
| Oct 28, 2025 | RBC Capital | downgrade | Outperform → Sector Perform | $72 | 55% |
| Oct 27, 2025 | Citigroup | downgrade | Buy → Neutral | $72 | 54% |
| Oct 27, 2025 | Leerink Partners | downgrade | Outperform → Market Perform | $72 | 51% |
| Oct 27, 2025 | Raymond James | downgrade | Strong Buy → Market Perform | $0 | 54% |
| Oct 27, 2025 | Bernstein | downgrade | Outperform → Market Perform | $72 | 52% |
| Oct 27, 2025 | Needham | downgrade | Buy → Hold | $65 | 50% |
| Oct 27, 2025 | HC Wainwright & Co. | downgrade | Buy → Neutral | $72 | 44% |
| Sep 22, 2025 | Evercore ISI Group | maintain | Outperform → Outperform | $65 | 58% |
| Sep 17, 2025 | Roth Capital | initiate | — → Buy | $62 | 53% |
| Sep 15, 2025 | B of A Securities | maintain | Buy → Buy | $65 | 53% |
| Sep 12, 2025 | HC Wainwright & Co. | maintain | Buy → Buy | $87 | 44% |
| Sep 10, 2025 | Needham | maintain | Buy → Buy | $65 | 50% |
| Sep 10, 2025 | Chardan Capital | maintain | Buy → Buy | $75 | 47% |
Price Target Trend
Apr 22, 2026 Latest: $72.71 Apr 26, 2026
EPS Estimates
+1y $-3.80
Lo: $-4.84 Hi: $-2.60
6 analysts ▲1
+1q $-1.33
Lo: $-1.61 Hi: $-1.01
6 analysts ▲1
0y $-5.05
Lo: $-6.53 Hi: $-3.24
8 analysts ▲1
0q $-1.30
Lo: $-1.59 Hi: $-0.98
6 analysts ▲1
Cross-Platform Signals
No cross-platform signals in the last 90 days